Zenosense, Inc. (OTCQB: ZENO), a healthcare technology company primarily focused on developing and marketing devices to detect the MRSA "Super-Bug" and to detect signs of lung cancer in exhaled breath, is pleased to announce that on 16 December 2014, the Company's development partner, Zenon Biosystem (Zenon) entered into a collaboration agreement for a lung cancer detection trial.
http://bit.ly/1BYDZWQ
No comments:
Post a Comment